Free Trial

KALA BIO Q1 2023 Earnings Report

KALA BIO logo
$4.68 -0.09 (-1.89%)
As of 12:09 PM Eastern

KALA BIO EPS Results

Actual EPS
-$6.99
Consensus EPS
-$5.10
Beat/Miss
Missed by -$1.89
One Year Ago EPS
N/A

KALA BIO Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

KALA BIO Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

KALA BIO Earnings Headlines

KALA BIO (KALA) to Release Quarterly Earnings on Friday
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
KALA BIO (KALA) Projected to Post Earnings on Thursday
See More KALA BIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KALA BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KALA BIO and other key companies, straight to your email.

About KALA BIO

KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

View KALA BIO Profile

More Earnings Resources from MarketBeat